SAB Biotherapeutics, Inc.
SABS
Positions held
Your positionsSABS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $262.95M | Enterprise value | $165.45M | Trailing P/E | — | Forward P/E | -3.03 |
| PEG | — | Price / book | 1.12 | Beta | 0.58 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -11.3% | ROA | -33.5% | Debt / equity | 0.02 |
| Current ratio | 9.22 | Free cash flow | -$28.84M | Analyst recommendation | none | Mean target | $11.64 |
| 52w high | $5.15 | 52w low | $2.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$22.5M | -$18.9M | -$16.9M | $45.4M | -$10.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$23.4M | -$20.0M | -$15.8M | -$12.7M | -$9.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
2026-09-22 · SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
2026-09-01 · SAB BIO to Participate in Upcoming Investor Conferences
2026-08-07 · SAB Biotherapeutics Q2 Earnings Call Highlights
2026-08-06 · SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
2026-08-06 · SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
2026-07-30 · SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
2026-07-15 · SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
Price (daily)
Full chart · RSI · MACD · patterns